We aimed to evaluate the effect of treatment with sarpogrelate, a serotonin 2A receptor antagonist, on circulating interleukin (IL)-18 levels in patients with diabetes and arteriosclerosis obliterans. Patients received sarpogrelate (100 mg 3 times daily) for 2 months. We evaluated the degree of cryaesthesia (a feeling of cold in the foot and toes) as the clinical outcome, and measured circulating IL-18, IL-6 and lipid protein concentrations. An improvement in clinical outcome occurred after initiation of sarpogrelate therapy; a significant decrease in IL-18 levels was observed after 2 months of therapy. Levels of IL-6 and lipid proteins, including triglyceride, total cholesterol and high-density lipoprotein cholesterol, were not significantly altered by treatment. Our data suggest that by reducing circulating IL-18 levels, sarpogrelate treatment may contribute to the inhibition of arteriosclerosis obliterans progression in patients with diabetes.
Introduction
Circulating inflammatory measures, including interleukin (IL)-6, are a risk factor for developing atherosclerosis, with or without diabetes.
1,2
IL-18, a cytokine synthesized by Kupffer cells, activates macrophages 3 and acts on T lymphocytes to promote the release of tumour necrosis factor-α from macrophages and interferon-γ from T-cells. 4 Circulating IL-18 levels are useful predictors of late restenosis after emergency coronary angioplasty in patients with acute myocardial infarction. 5 Arteriosclerosis obliterans (ASO) is defined as peripheral arterial occlusive disease including symptoms of cryaesthesia (a feeling of cold in the foot and toes) and walking or resting pain. We studied patients with ASO and diabetes because sarpogrelate can be given to these patients to improve the symptoms.
Serotonin is a naturally occurring vasoactive substance and has been associated with vascular inflammation leading to atherosclerosis. 6 Sarpogrelate hydrochloride is a serotonin 2A receptor antagonist, and is used clinically to treat cutaneous ulcers and ischaemic change resulting from atherosclerosis. We describe the effect of sarpogrelate on circulating IL-18 and IL-6 concentrations in patients with diabetes and ASO.
Patients and methods
The Hospital of Kanazawa Medical University Ethics Committee approved the study.
PATIENTS
Patients with diabetes and ASO who had developed cryaesthesia were enrolled in this study; all gave informed consent. Patients already receiving medication for ASO, such as antiplatelet drugs or vasodilatory agents, were excluded from the study.
TREATMENT
Patients received 100 mg of sarpogrelate (Mitsubishi Pharma Corporation, Osaka, Japan), three times daily for 2 months. Patients continued to take medication throughout the trial to control diabetes mellitus.
MEASUREMENT OF CLINICAL OUTCOME
The degree of cryaesthesia, defined as a feeling of cold in the foot and toes, was evaluated at baseline and after 2 weeks, 1 month and 2 months of treatment using a visual analogue scale (0 -10). 7 Changes in cryaesthesia were considered to be the clinical outcome.
CIRCULATING CONCENTRATION MEASUREMENTS
Blood samples were taken from each patient before treatment (baseline) and 2 weeks, 1 month and 2 months after the start of sarpogrelate treatment. Circulating concentrations of IL-18 and IL-6 were measured using an enzyme immunoassay kit and a combination of chemiluminescence and an enzyme immunoassay kit, respectively, according to the manufacturer's instructions (Medical & Biological Laboratories Co. Ltd, Nagoya, Japan; R&D Systems Inc., Minneapolis, MN, USA, respectively).
Circulating concentrations of lipid proteins, including total cholesterol, highdensity lipoprotein (HDL) cholesterol and triglyceride, were also examined using standard methods.
STATISTICAL ANALYSIS
Data are expressed as mean values ± SD. The association between baseline and during/after treatment results was analysed by one-tailed analysis of variance. A P-value < 0.05 was considered statistically significant.
Results
Eight patients were recruited to the study and their mean age (± SD) was 64 ± 13 years. The male to female ratio was three to one.
A significant decrease (P < 0.01) in cryaesthesia in the foot and toes was observed (0.7 ± 1.1 at 1 month versus 10 ± 0 at baseline), confirming a good clinical outcome following sarpogrelate treatment.
Circulating IL-18, IL-6, triglyceride, total cholesterol and HDL-cholesterol levels at the various time points are shown in Table 1 . The circulating IL-18 concentration was significantly reduced 2 months after the start of sarpogrelate treatment, whereas the IL-6 concentration in blood was not significantly changed during the treatment course. No adverse effects attributable to sarpogrelate were observed.
Discussion
Serotonin, a decarboxylated derivative of the amino acid tryptophan, is a major secretory product of activated platelets. 8 In the vascular system, serotonin induces proliferation, contraction and migration of smooth muscle cells, and platelet aggregation. 9, 10 Coronary sinus serotonin levels have been reported to be significantly elevated (P < 0.05) in patients with acute coronary syndrome. 11 Serotonin receptors have been classified according to their different signal transduction mechanisms. 8 Sarpogrelate, a serotonin 2A receptor antagonist, is known to have an effect on ischaemic symptoms, such as a feeling of cold in the foot and toes, due to ASO. 12 By blocking the serotonin receptor, sarpogrelate causes vasodilatation and inhibition of platelet aggregation. This drug has also been reported to be effective for diabetic nephropathy through the reduction in serotonin binding. 13 
